Arriva Pharmaceuticals

Arriva Pharmaceuticals, Inc. was founded in 1997 as a private biopharmaceutical company focused on the development and commercialization of recombinant protease inhibitors for the treatment of various human diseases. The company has developed technology for the large-scale production of stable, non-animal sourced recombinant proteins in yeast. Using this technology, GMP (Good Manufacturing Practice) clinical-grade recombinant alpha1-antitrypsin (AAT) has been used in clinical trials for respiratory and dermatological indications, and maspin will be produced for the treatment of breast and prostate cancer. In January 2001, the company changed its name from AlphaOne Pharmaceuticals, Inc. to Arriva Pharmaceuticals, Inc. to reflect an expansion from a single-product focus to a more diversified pharmaceutical pipeline.